Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 7/20 | 0.46 |
| ▸ | PRKCG | P05129 | 7/20 | 0.46 |
| ▸ | PRKCB | P05771 | 7/20 | 0.46 |
| ▸ | PRKCA | P17252 | 7/20 | 0.46 |
| ▸ | PRKCH | P24723 | 7/20 | 0.46 |
| ▸ | PRKCI | P41743 | 7/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 7/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 7/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 7/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 7/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | PRKACA | P17612 | 5/20 | 0.46 |
| ▸ | PRKACG | P22612 | 5/20 | 0.46 |
| ▸ | PRKACB | P22694 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23951469 | 1.00 | PRKD3 (0.46) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL30114565 | 1.00 | PRKD3 (0.46) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL23924195 | 0.80 | P2RX7 (0.48) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL23924196 | 0.80 | P2RX7 (0.48) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL9543831 | 0.78 | PRKD3 (0.55) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL30114348 | 0.77 | ROCK2 (0.50) | MEN1KMT2AMAPK1HTTROCK2 | |
| SCHEMBL23951813 | 0.77 | ROCK2 (0.50) | MEN1KMT2AMAPK1HTTROCK2 | |
| SCHEMBL23923918 | 0.77 | ROCK2 (0.50) | MEN1KMT2AMAPK1HTTROCK2 | |
| SCHEMBL23951468 | 0.75 | P2RX7 (0.49) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL6238571 | 0.75 | PRKCZ (0.57) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | claimed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | claimed |
| CN-115427394-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | PRKD3 1591/4885PRKCG 2026/4885PRKCB 1086/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | PRKD3 1591/4885PRKCG 2026/4885PRKCB 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.